Two‐site evaluation of a new workflow for the detection of malignant cells on the Sysmex XN‐1000 body fluid analyzer
- 12 March 2020
- journal article
- research article
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 42 (5) , 544-551
Abstract
Introduction: The presence of high fluorescent cells (HF‐BF) on the Sysmex XN‐1000 hematology analyzers has gained interest regarding the prediction of malignant cells in body fluids, but lacks sensitivity. We aimed to increase this sensitivity by combining HF‐BF value, automated results, and clinical information.Methods: We evaluated a new workflow for the management of body fluids in the hematology laboratory, including the HF‐BF criterion and clinical information. In two laboratories, 1623 serous fluids were retrospectively analyzed on the XN‐1000 BF mode. All samples were morphologically screened for malignant cells. Optimal HF‐BF cutoffs were determined to predict their presence. Thereafter, the added value of clinical information was evaluated. Other reflex testing rules (eosinophilic count >5% and presence of the WBC Abnormal Scattergram flag) were also used to refine our workflow.Results: Optimal HF‐BF cutoffs in the two hematology centers were 108 and 45 cells/µL, yielding a sensitivity/specificity of 66.7/93.6% and 86.8/66.6% for malignant cell detection. When adding clinical information, sensitivity/specificity evolved to 100.0/68.9% and 100.0%/not determined. Of 104 samples containing malignant cells, 97 had positive clinical information; the remainder had a HF‐BF > cutoff.Conclusion: Combining clinical information and HF‐BF reached 100% sensitivity for malignant cell detection in body fluid analysis. Lack of robustness of the optimal HF‐BF cutoff deserves the use of local cutoffs. Rapid automated results reporting from the XN‐1000 BF mode are also feasible in clinical practice. Prospective evaluation of the workflow is needed before its implementation in clinical practice.Keywords
This publication has 23 references indexed in Scilit:
- Utility of the XN-1000 research mode for leukocytes counting in ascitic and pleural fluidsInternational Journal of Laboratory Hematology, 2020
- EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosisJournal of Hepatology, 2018
- Evaluation of body fluid mode of Sysmex XN-9000 for white blood cell counts in cerebrospinal fluidJournal of Laboratory and Precision Medicine, 2018
- Two‐site evaluation of the diagnostic performance of the Sysmex XN Body Fluid (BF) module for cell count and differential in Cerebrospinal FluidInternational Journal of Laboratory Hematology, 2017
- Opportunities and drawbacks of nonstandard body fluid analysisClinical Chemistry and Laboratory Medicine (CCLM), 2017
- Body Fluid Cell Counts by Automated MethodsClinics In Laboratory Medicine, 2015
- Clinical relevance and contemporary methods for counting blood cells in body fluids suspected of inflammatory diseaseClinical Chemistry and Laboratory Medicine (CCLM), 2015
- Validation of the body fluid module on the new Sysmex XN-1000 for counting blood cells in cerebrospinal fluid and other body fluidsClinical Chemistry and Laboratory Medicine (CCLM), 2012
- Investigation of a unilateral pleural effusion in adults: British Thoracic Society pleural disease guideline 2010Thorax, 2010
- Ascitic fluid analysis in malignancy-related ascitesHepatology, 1988